Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Non Small Cell Lung Cancer NSCLC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Ordos Central Hospital, Neimeng, Neimeng, China

  • Peking University Cancer Hospital (Inner Mongolia Campus), Neimeng, Neimeng, China

  • Affiliated Hospital of Hebei University, Baoding, China

  • Baotou Cancer Hospital, Baotou, China

  • Peking University Cancer Hospital & Institute, Beijing, China

    Contact: Study coordinator (Minglei Zhuo) · minglei1978@163.com · +86 88196456
  • Beijing Chest Hospital, Capital Medical University, Beijing, China

  • Beijing Daxing District People's Hospital, Beijing, China

  • Peking Union Medical College Hospital, Beijing, China

  • Peking University People's Hospital, Beijing, China

  • Peking University Third Hospital, Beijing, China

  • The Second Hospital of Dalian Medical University, Dalian, China

  • Tianjin Medical University Cancer Institute & Hospital, Tianjin, China